← Leaderboards
Jeremy Blitzer
Potrero Hill Therapeutics, Inc.
$2,467,498
Attributed
$4,934,995
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–22$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,934,995 · 2
By mechanism
R44$4,709,995 · 1
R43$225,000 · 1
Top collaborators
- Scott A Summers6 shared
Others in their field
Other Emerging Leaders on “Hypertriglyceridemia”
- Gabi Hanna · Lamassu Pharma Inc.$3,317,651
- David McCormack · Iit Research Institute$2,597,086
- Joshua Wiley Knowles · Stanford University$2,434,492
- Frank Sciavolino · Thetis Pharmaceuticals, Llc$2,278,470
- Jenny E. Kanter · University Of Washington$2,089,357
- Ren Zhang · Wayne State University$1,932,275
Research focus
HypertriglyceridemiaImpaired Fasting GlycaemiaGrantHyperglycemiaEpidemicFda ApprovedEnzymesFundingDihydroceramide DesaturaseHepatocyteCardiovascular DiseasesAnabolismFatty LiverBiological AvailabilityCellsBlindnessDesaturaseDiabetes MellitusBlood LipidCeramidesEnd Stage Renal FailureHep3bBaseIncidence
Grant awards (6)
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$1,069,999
R44 · FY2022 · DK · contact PI
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$1,069,999
R44 · FY2021 · DK · contact PI
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$1,069,999
R44 · FY2020 · DK · contact PI
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$749,999
R44 · FY2019 · DK · contact PI
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$749,999
R44 · FY2018 · DK · contact PI
Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases$225,000
R43 · FY2017 · DK · contact PI